{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:22Z","timestamp":1793239402076,"version":"4.5.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI158160"],"award-info":[{"award-number":["R01 AI158160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI145542"],"award-info":[{"award-number":["R01 AI145542"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH115860"],"award-info":[{"award-number":["R01 MH115860"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS034239"],"award-info":[{"award-number":["R01 NS034239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS036126"],"award-info":[{"award-number":["R01 NS036126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS126089"],"award-info":[{"award-number":["R01 NS126089"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.addr.2023.115009","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T22:38:35Z","timestamp":1689201515000},"page":"115009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection"],"prefix":"10.1016","volume":"200","author":[{"given":"Mohammad","family":"Ullah Nayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Sillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmudul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijanee","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrafi","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam","family":"Thai Hoang Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0005","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/QAI.0000000000000993","article-title":"PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials","volume":"72","author":"Dimitrov","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"suppl 3","key":"10.1016\/j.addr.2023.115009_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.addr.2023.115009_b0015","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiat."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.9745\/GHSP-D-13-00010","article-title":"Use of modern contraception increases when more methods become available: analysis of evidence from 1982\u20132009","volume":"1","author":"Ross","year":"2013","journal-title":"Glob Health Sci Pract"},{"key":"10.1016\/j.addr.2023.115009_b0025","unstructured":"Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States, 2023."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0030","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000003085","article-title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","volume":"36","author":"Mills","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0035","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-022-30902-7","article-title":"Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation","volume":"13","author":"Deodhar","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0040","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","article-title":"Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research","volume":"17","author":"Cobb","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"issue":"12","key":"10.1016\/j.addr.2023.115009_b0045","doi-asserted-by":"crossref","first-page":"e114700","DOI":"10.1371\/journal.pone.0114700","article-title":"High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy","volume":"9","author":"Meyers","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals","volume":"24","author":"Ray","year":"2010","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350200600401","article-title":"Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience","volume":"6","author":"van Heeswijk","year":"2001","journal-title":"Antivir. Ther."},{"issue":"13","key":"10.1016\/j.addr.2023.115009_b0070","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"18","key":"10.1016\/j.addr.2023.115009_b0080","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and development of anti-HIV therapeutic agents: progress towards improved HIV medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0085","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11904-011-0078-4","article-title":"Preexposure prophylaxis for HIV prevention","volume":"8","author":"Kelesidis","year":"2011","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/QAI.0000000000001374","article-title":"Characterization of HIV Seroconverters in a TDF\/FTC PrEP Study: HPTN 067\/ADAPT","volume":"75","author":"Sivay","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"11","key":"10.1016\/j.addr.2023.115009_b0100","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiz383","article-title":"Efficacy of oral tenofovir alafenamide\/emtricitabine combination or single-agent tenofovir alafenamide against vaginal simian human immunodeficiency virus infection in macaques","volume":"220","author":"Massud","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.addr.2023.115009_b0105","unstructured":"Administration, U.S.F.D., Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use. 2012: www.fda.gov."},{"key":"10.1016\/j.addr.2023.115009_b0110","unstructured":"Administration, U.S.F.D., FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. 2019: www.fda.gov."},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.addr.2023.115009_b0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijpharm.2018.10.017","article-title":"Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles","volume":"552","author":"Krovi","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0000000000000597","article-title":"Long-acting injectable cabotegravir for the prevention of HIV infection","volume":"15","author":"Clement","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.addr.2023.115009_b0135","doi-asserted-by":"crossref","unstructured":"K.K. Scarsi S. Swindells The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data? J Int Assoc Provid AIDS Care 20 2021 23259582211009011.","DOI":"10.1177\/23259582211009011"},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0140","doi-asserted-by":"crossref","first-page":"e1001511","DOI":"10.1371\/journal.pmed.1001511","article-title":"Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa","volume":"10","author":"Haberer","year":"2013","journal-title":"PLoS Med."},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0145","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/17425247.2022.2135699","article-title":"Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges","volume":"19","author":"Agrahari","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0150","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14787210.2022.2081153","article-title":"Cabotegravir\/Rilpivirine: the last FDA-approved drug to treat HIV","volume":"20","author":"Taki","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.addr.2023.115009_b0155","unstructured":"E.M. Agency, First long-acting injectable antiretroviral therapy for HIV recommended for approval. 2020: www.ema.europa.eu."},{"key":"10.1016\/j.addr.2023.115009_b0160","unstructured":"V. Healthcare, ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV. 2020: www.viivhealthcare.com."},{"key":"10.1016\/j.addr.2023.115009_b0165","unstructured":"Administration, U.S.F.D., FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. 2021: www.fda.gov."},{"key":"10.1016\/j.addr.2023.115009_b0170","unstructured":"V. Healthcare, ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF CABENUVA (CABOTEGRAVIR, RILPIVIRINE) FOR USE EVERY TWO MONTHS, EXPANDING THE LABEL OF THE FIRST AND ONLY COMPLETE LONG-ACTING HIV TREATMENT, in Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine. 2022: www.viivhealthcare.com."},{"key":"10.1016\/j.addr.2023.115009_b0175","unstructured":"V. Healthcare, ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD, in US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections. 2022, www.viivhealthcare.com."},{"issue":"11","key":"10.1016\/j.addr.2023.115009_b0180","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2023.115009_b0185","unstructured":"J. Johnson, U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen in CABENUVA offers virologically suppressed adolescents 12 years of age or older living with HIV-1 an injectable treatment option with as few as six dosing days per year. 2022: www.jnj.com."},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"6","key":"10.1016\/j.addr.2023.115009_b0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0200","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115009_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113849","article-title":"Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention","volume":"176","author":"Krovi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115009_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100303","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women","volume":"21","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10101","key":"10.1016\/j.addr.2023.115009_b0215","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.115009_b0220","doi-asserted-by":"crossref","unstructured":"G.H.R. Smith, et al., Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis 8(9) (2021) ofab439.","DOI":"10.1093\/ofid\/ofab439"},{"issue":"12","key":"10.1016\/j.addr.2023.115009_b0225","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.addr.2023.115009_b0230","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"issue":"10267","key":"10.1016\/j.addr.2023.115009_b0240","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.addr.2023.115009_b0245","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/QAD.0000000000003085","article-title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","volume":"36","author":"Mills","year":"2022","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0255","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000467","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor","volume":"13","author":"Markowitz","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.addr.2023.115009_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113380","article-title":"An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors","volume":"217","author":"Sun","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"6514","key":"10.1016\/j.addr.2023.115009_b0265","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0270","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/jac\/dkx208","article-title":"Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients","volume":"72","author":"Perrier","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0275","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7822","key":"10.1016\/j.addr.2023.115009_b0280","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.115009_b0285","unstructured":"R. Begley, J. L., M. Rhee, et al., GS-6207 sustained delivery formulation supports 6-month dosing interval, in: 2020 International AIDS Conference; Virtual; July 6\u201310. 2020."},{"key":"10.1016\/j.addr.2023.115009_b0290","unstructured":"R. Begley, R.M., S.K. West, et al., PK, food effect, and safety of oral GS-6207, a novel HIV-1 capsid inhibitor, in: 2020 Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2020."},{"issue":"19","key":"10.1016\/j.addr.2023.115009_b0295","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 Infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0300","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2023.115009_b0305","unstructured":"Administration, U.S.F.D., FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention, in Drug Given Every Two Months Rather Than Daily Pill is Important Tool in Effort to End the HIV Epidemic. 2021: www.fda.gov."},{"key":"10.1016\/j.addr.2023.115009_b0310","unstructured":"V. Healthcare EUROPEAN MEDICINES AGENCY VALIDATES ViiV HEALTHCARE\u2019S MARKETING AUTHORISATION APPLICATION FOR CABOTEGRAVIR LONG-ACTING INJECTABLE FOR HIV PREVENTION 2022."},{"key":"10.1016\/j.addr.2023.115009_b0315","unstructured":"W.H. Organization, WHO recommends long-acting cabotegravir for HIV prevention, in New WHO guidelines advise countries to deliver long-acting cabotegravir as part of comprehensive approach to HIV prevention. 2022: www.who.int."},{"issue":"22","key":"10.1016\/j.addr.2023.115009_b0320","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0325","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"6","key":"10.1016\/j.addr.2023.115009_b0330","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14787210.2023.2203913","article-title":"Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options","volume":"21","author":"Tuan","year":"2023","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0335","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0340","article-title":"Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa","volume":"7","author":"Moyo","year":"2022","journal-title":"Trop Med Infect. Dis."},{"issue":"10337","key":"10.1016\/j.addr.2023.115009_b0345","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/15284336.2018.1511346","article-title":"Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial","volume":"19","author":"Murray","year":"2018","journal-title":"HIV Clin. Trials"},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0355","doi-asserted-by":"crossref","first-page":"e25408","DOI":"10.1002\/jia2.25408","article-title":"Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)","volume":"22","author":"Tolley","year":"2019","journal-title":"J. Int. AIDS Soc."},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0360","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1016\/S2352-3018(21)00127-2","article-title":"Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study","volume":"8","author":"Schaefer","year":"2021","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.addr.2023.115009_b0365","doi-asserted-by":"crossref","first-page":"e25747","DOI":"10.1002\/jia2.25747","article-title":"Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States","volume":"24","author":"Liu","year":"2021","journal-title":"J. Int. AIDS Soc."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0370","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10461-012-0248-4","article-title":"Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use","volume":"16","author":"Montgomery","year":"2012","journal-title":"AIDS Behav."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0375","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s10461-012-0215-0","article-title":"High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women","volume":"16","author":"van der Straten","year":"2012","journal-title":"AIDS Behav."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0380","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/ciy654","article-title":"Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women","volume":"68","author":"Chen","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"22","key":"10.1016\/j.addr.2023.115009_b0385","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0390","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","article-title":"Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study","volume":"8","author":"Nel","year":"2021","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0395","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","article-title":"Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study","volume":"8","author":"Baeten","year":"2021","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0400","doi-asserted-by":"crossref","first-page":"e0147743","DOI":"10.1371\/journal.pone.0147743","article-title":"Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-saharan Africa","volume":"11","author":"Nel","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0405","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S2352-3018(20)30165-X","article-title":"Chasing the cabotegravir tail: implications for prevention","volume":"7","author":"Scarsi","year":"2020","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0410","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2023.115009_b0415","unstructured":"Health, C.f.D.C.a.P.U.P. and Service, Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 Update: a clinical practice guideline. 2021."},{"key":"10.1016\/j.addr.2023.115009_b0420","article-title":"The long-acting cabotegravir tail as an implementation challenge: planning for safe discontinuation","author":"Meyers","year":"2022","journal-title":"AIDS Behav."},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0425","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/QAI.0000000000002793","article-title":"Pills, injections, rings, or implants? Prep formulation preferences of PrEP-experienced african women for HIV prevention","volume":"88","author":"Ngure","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0430","doi-asserted-by":"crossref","first-page":"e25170","DOI":"10.1002\/jia2.25170","article-title":"Perspectives of South African youth in the development of an implant for HIV prevention","volume":"21","author":"Krogstad","year":"2018","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0435","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"17","key":"10.1016\/j.addr.2023.115009_b0440","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000000421","article-title":"Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood","volume":"28","author":"Freeling","year":"2014","journal-title":"AIDS"},{"issue":"1\u20133","key":"10.1016\/j.addr.2023.115009_b0445","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0450","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5588\/ijtld.17.0486","article-title":"Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges","volume":"22","author":"Swindells","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.addr.2023.115009_b0455","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2020.05.022","article-title":"Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs","volume":"324","author":"Surve","year":"2020","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0460","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation","volume":"54","author":"van 't Klooster","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.115009_b0465","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpb.2018.04.009","article-title":"Towards a Maraviroc long-acting injectable nanoformulation","volume":"138","author":"Tatham","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115009_b0470","doi-asserted-by":"crossref","unstructured":"Sezer, A.D., Recent advances in novel drug carrier systems. 2012.","DOI":"10.5772\/2889"},{"key":"10.1016\/j.addr.2023.115009_b0475","series-title":"Design of nanostructures for versatile therapeutic applications","author":"Grumezescu","year":"2018"},{"key":"10.1016\/j.addr.2023.115009_b0480","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fchem.2018.00323","article-title":"Spectroscopic studies as a toolbox for biophysical and chemical characterization of lipid-based nanotherapeutics","volume":"6","author":"Fernandes","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2023.115009_b0485","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.addr.2023.115009_b0490","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0495","first-page":"155","article-title":"Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques","volume":"42","author":"Kinman","year":"2006","journal-title":"JAIDS J. Acquired Immune Deficiency Syndromes"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0500","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","article-title":"Lipid\u2013drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"JAIDS J. Acquired Immune Deficiency Syndromes"},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0505","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1002\/jps.22529","article-title":"Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention","volume":"100","author":"Alukda","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115009_b0510","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2019.04.010","article-title":"Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV","volume":"167","author":"Kudalkar","year":"2019","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0515","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01475-16","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0520","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jps.2600760902","article-title":"Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design","volume":"76","author":"Hansch","year":"1987","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115009_b0525","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.06.005","article-title":"Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: a humanized mouse model study","volume":"156","author":"Mandal","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2023.115009_b0530","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s11095-017-2255-7","article-title":"Pharmacokinetic and tissue distribution profile of long acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model","volume":"34","author":"Prathipati","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115009_b0535","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0540","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02320-20","article-title":"A concept evaluation study of a new combination bictegravir plus tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 preexposure prophylaxis","volume":"65","author":"Mandal","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0545","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","article-title":"Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission","volume":"31","author":"Mandal","year":"2017","journal-title":"AIDS (London, England)"},{"issue":"2","key":"10.1016\/j.addr.2023.115009_b0550","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"J. Virus Erad."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0555","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0560","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1038\/s41467-021-25690-5","article-title":"Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles","volume":"12","author":"Cobb","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.115009_b0565","doi-asserted-by":"crossref","unstructured":"S. Das et al. An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression Sci Adv 8 51 2022 p. eade9582.","DOI":"10.1126\/sciadv.ade9582"},{"key":"10.1016\/j.addr.2023.115009_b0570","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.2147\/IJN.S215447","article-title":"Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"15","key":"10.1016\/j.addr.2023.115009_b0575","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2217\/nnm-2016-0164","article-title":"Development and characterization of a long-acting nanoformulated abacavir prodrug","volume":"11","author":"Singh","year":"2016","journal-title":"Nanomedicine (Lond.)"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0580","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1097\/QAI.0000000000001170","article-title":"Creation of a long-acting nanoformulated 2',3'-dideoxy-3'-thiacytidine","volume":"74","author":"Guo","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2023.115009_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119476","article-title":"A long acting nanoformulated lamivudine ProTide","volume":"223","author":"Smith","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115009_b0590","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","article-title":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","volume":"151","author":"Zhou","year":"2018","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0595","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Sillman","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0600","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2023.115009_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120889","article-title":"Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations","volume":"607","author":"Khuroo","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0610","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41467-019-09354-z","article-title":"Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies","volume":"10","author":"Hobson","year":"2019","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.addr.2023.115009_b0615","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1039\/D2TB00825D","article-title":"Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants","volume":"10","author":"Shakil","year":"2022","journal-title":"J. Mater. Chem. B"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0620","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0625","doi-asserted-by":"crossref","first-page":"17","DOI":"10.9745\/GHSP-D-17-00396","article-title":"Liftoff: the blossoming of contraceptive implant use in Africa","volume":"6","author":"Jacobstein","year":"2018","journal-title":"Glob Health Sci Pract"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0630","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11040173","article-title":"Development of a transdermal delivery system for tenofovir alafenamide, a prodrug of tenofovir with potent antiviral activity against HIV and HBV","volume":"11","author":"Puri","year":"2019","journal-title":"Pharmaceutics"},{"issue":"Suppl 1","key":"10.1016\/j.addr.2023.115009_b0635","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13625180801959931","article-title":"The effects of Implanon on menstrual bleeding patterns","volume":"13","author":"Mansour","year":"2008","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.addr.2023.115009_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113912","article-title":"Drug release from in situ forming implants and advances in release testing","volume":"178","author":"Wang","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0645","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COH.0000000000000599","article-title":"Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1","volume":"15","author":"Markowitz","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0650","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","volume":"7","author":"Sch\u00fcrmann","year":"2020","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0655","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0660","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0665","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jiz271","article-title":"Once-weekly oral dosing of MK-8591 protects male rhesus macaques from intrarectal challenge with SHIV109CP3","volume":"221","author":"Markowitz","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.addr.2023.115009_b0670","unstructured":"Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant. 2019."},{"key":"10.1016\/j.addr.2023.115009_b0675","unstructured":"Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection. December 2021."},{"key":"10.1016\/j.addr.2023.115009_b0680","unstructured":"Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection. September 2022."},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0685","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/QAI.0b013e3182717c98","article-title":"Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study","volume":"61","author":"Chen","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0690","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1\u2013positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"JAIDS J. Acquired Immune Deficiency Syndromes"},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0695","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2174","article-title":"Tenofovir alafenamide for the treatment of chronic hepatitis B monoinfection","volume":"38","author":"Childs-Kean","year":"2018","journal-title":"Pharmacotherapy: J. Human Pharmacol. DrugTherapy"},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0700","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/pharmaceutics11070315","article-title":"Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP)","volume":"11","author":"Johnson","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.115009_b0705","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","article-title":"A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis","volume":"33","author":"Schlesinger","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115009_b0710","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.569373","article-title":"Multispecies evaluation of a long-acting tenofovir alafenamide subdermal implant for HIV prophylaxis","volume":"11","author":"Gunawardana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2023.115009_b0715","unstructured":"M. Gunawardana et al., MARY ANN LIEBERT, INC 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801, Multispecies, in vivo evaluation of subdermal implants delivering tenofovir alafenamide: Of mice, dogs and sheep, in: AIDS RESEARCH AND HUMAN RETROVIRUSES 2018 USA."},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0720","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1039\/D0LC00121J","article-title":"Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery","volume":"20","author":"Di Trani","year":"2020","journal-title":"Lab Chip"},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0725","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/adhm.201200214","article-title":"Silicon micro-and nanofabrication for medicine","volume":"2","author":"Fine","year":"2013","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0730","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jconrel.2013.09.028","article-title":"Leveraging nanochannels for universal, zero-order drug delivery in vivo","volume":"172","author":"Ferrati","year":"2013","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0735","article-title":"Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates","volume":"4","author":"Pons-Faudoa","year":"2021","journal-title":"Adv Ther (Weinh)"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0740","doi-asserted-by":"crossref","first-page":"e01893","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.115009_b0745","unstructured":"C. Bagia, T. Shah, V. Sant, Development of novel accelerated stability testing models for tenofovir alafenamide (TAF) in long-acting implants for HIV prevention, in: Proceedings of the Controlled Release Society, Las Vegas, NV, USA, 2020. 27."},{"key":"10.1016\/j.addr.2023.115009_b0750","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.037","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis","volume":"306","author":"Pons-Faudoa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115009_b0755","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jconrel.2020.12.024","article-title":"Design and testing of a cabotegravir implant for HIV prevention","volume":"330","author":"Karunakaran","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0760","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41467-023-36330-5","article-title":"Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection","volume":"14","author":"Young","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.115009_b0765","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","article-title":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","volume":"286","author":"Chua","year":"2018","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0770","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10461-021-03512-5","article-title":"Does the ring work? Perceptions and understanding of the efficacy of a dapivirine vaginal ring for HIV prevention amongst women in a placebo-controlled trial","volume":"26","author":"Etima","year":"2022","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2023.115009_b0775","unstructured":"K. Ngure, Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH: 67% prefer ring vs 31% oral PrEP in Conference on Retroviruses and Opportunistic Infections. 2022: Virtual."},{"issue":"Suppl 1","key":"10.1016\/j.addr.2023.115009_b0780","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.antiviral.2010.09.003","article-title":"Advances in microbicide vaginal rings","volume":"88","author":"Malcolm","year":"2010","journal-title":"Antiviral Res."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0785","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/jac\/dks097","article-title":"Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection","volume":"67","author":"Mesquita","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0790","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","article-title":"Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir","volume":"39","author":"Johnson","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0795","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s11095-017-2224-1","article-title":"A dose ranging pharmacokinetic evaluation of IQP-0528 released from intravaginal rings in non-human primates","volume":"34","author":"Su","year":"2017","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0800","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cid\/ciy653","article-title":"Phase 1 safety and pharmacokinetics study of MK-2048\/Vicriviroc (MK-4176)\/MK-2048A intravaginal rings","volume":"68","author":"Hoesley","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.addr.2023.115009_b0805","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1128\/AAC.01431-12","article-title":"A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.addr.2023.115009_b0810","doi-asserted-by":"crossref","first-page":"e0199778","DOI":"10.1371\/journal.pone.0199778","article-title":"Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women","volume":"13","author":"Thurman","year":"2018","journal-title":"PLoS One"},{"issue":"40","key":"10.1016\/j.addr.2023.115009_b0815","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges","volume":"110","author":"Smith","year":"2013","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0820","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2352-3018(19)30145-6","article-title":"Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial","volume":"6","author":"Keller","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2023.115009_b0825","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.addr.2021.04.002","article-title":"Microarray patches: Breaking down the barriers to contraceptive care and HIV prevention for women across the globe","volume":"173","author":"Paredes","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115009_b0830","article-title":"Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches","volume":"13","author":"Paredes","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.addr.2023.115009_b0835","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mser.2016.03.001","article-title":"Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development","volume":"104","author":"Larra\u00f1eta","year":"2016","journal-title":"Mater. Sci. Eng. R. Rep."},{"key":"10.1016\/j.addr.2023.115009_b0840","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","article-title":"Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension","volume":"292","author":"Mc Crudden","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115009_b0845","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpb.2021.04.024","article-title":"Etravirine-loaded dissolving microneedle arrays for long-acting delivery","volume":"165","author":"Rojekar","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115009_b0850","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jconrel.2022.06.028","article-title":"Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV pre-exposure prophylaxis","volume":"348","author":"Volpe-Zanutto","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115009_b0855","doi-asserted-by":"crossref","unstructured":"I.A. Tekko, et al., Novel Bilayer Microarray Patch-Assisted Long-Acting Micro-Depot Cabotegravir Intradermal Delivery for HIV Pre-Exposure Prophylaxis (Adv. Funct. Mater. 9\/2022). Advanced Functional Materials, 2022. 32(9): p. 2270059.","DOI":"10.1002\/adfm.202270059"},{"key":"10.1016\/j.addr.2023.115009_b0860","doi-asserted-by":"crossref","unstructured":"A. Puri et al., Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV Pharmaceutics 11 2019 10.3390\/pharmaceutics11040173.","DOI":"10.3390\/pharmaceutics11040173"},{"key":"10.1016\/j.addr.2023.115009_b0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119342","article-title":"Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats","volume":"582","author":"Jiang","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0870","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2012.07.039","article-title":"Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations","volume":"162","author":"Pattani","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115009_b0875","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2017.10.026","article-title":"Long-lived tissue resident HIV-1 specific memory CD8+ T cells are generated by skin immunization with live virus vectored microneedle arrays","volume":"268","author":"Zaric","year":"2017","journal-title":"J. Control. Release"},{"issue":"33","key":"10.1016\/j.addr.2023.115009_b0880","doi-asserted-by":"crossref","first-page":"16473","DOI":"10.1073\/pnas.1902179116","article-title":"Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination","volume":"116","author":"Boopathy","year":"2019","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.addr.2023.115009_b0885","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0890","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","article-title":"An overview of human anti-HIV-1 neutralizing antibodies against diverse epitopes of HIV-1","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0895","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.addr.2023.115009_b0900","doi-asserted-by":"crossref","first-page":"45163","DOI":"10.1038\/srep45163","article-title":"Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library","volume":"7","author":"Khan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2023.115009_b0905","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly neutralizing antibodies for HIV-1 prevention","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Immunol."},{"issue":"7557","key":"10.1016\/j.addr.2023.115009_b0910","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.addr.2023.115009_b0915","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0920","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2023.115009_b0925","unstructured":"Gilead. 2023."},{"issue":"10","key":"10.1016\/j.addr.2023.115009_b0930","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","article-title":"Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate\/Emtricitabine for HIV Prevention: HPTN 084","volume":"225","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.addr.2023.115009_b0935","first-page":"187","article-title":"Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV\/AIDS","volume":"20","author":"Soriano","year":"2018","journal-title":"AIDS Rev."},{"issue":"11","key":"10.1016\/j.addr.2023.115009_b0940","doi-asserted-by":"crossref","first-page":"766","DOI":"10.7326\/0003-4819-154-11-201106070-00345","article-title":"Thirty years of HIV and AIDS: future challenges and opportunities","volume":"154","author":"Dieffenbach","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2023.115009_b0945","doi-asserted-by":"crossref","unstructured":"Thirty Years of HIV and AIDS: Future Challenges and Opportunities. Annals of Internal Medicine 154(11) (2011) 766-771.","DOI":"10.7326\/0003-4819-154-11-201106070-00345"},{"issue":"8","key":"10.1016\/j.addr.2023.115009_b0950","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00018-022-04421-z","article-title":"HIV cure strategies: which ones are appropriate for Africa?","volume":"79","author":"Abana","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2023.115009_b0955","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","article-title":"Deep latency: a new insight into a functional HIV cure","volume":"45","author":"Elsheikh","year":"2019","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.addr.2023.115009_b0960","doi-asserted-by":"crossref","first-page":"e26006","DOI":"10.1002\/jia2.26006","article-title":"Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study","volume":"25","author":"Garris","year":"2022","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.addr.2023.115009_b0965","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0970","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after <em>CCR5<\/em>\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"The Lancet HIV"},{"issue":"7","key":"10.1016\/j.addr.2023.115009_b0975","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"5","key":"10.1016\/j.addr.2023.115009_b0980","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","article-title":"Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine","volume":"28","author":"Bessesen","year":"1999","journal-title":"Clin. Infect. Dis."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23003241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23003241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:36:30Z","timestamp":1759210590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23003241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":196,"alternative-id":["S0169409X23003241"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.115009","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.115009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115009"}}